

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BRANDS *et al.*

Appl. No.: 10/588,285

Filed: September 22, 2008

For: **ALKALINE PHOSPHATASE
FOR TREATING AN
INFLAMMATORY DISEASE OF
THE GASTRO-INTESTINAL
TRACT** (*as amended herewith*)

Confirmation No.: 6440

Art Unit: 1657

Examiner: Ralph J. GITOMER

Atty. Docket: 3151.0030001/TJS/BNC

Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms PTO/SB/08a equivalent and PTO/SB/08b equivalent are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. § 1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. This Supplemental IDS is a continuation of the IDS filed on July 19, 2011.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. 37 C.F.R. § 1.97(c).

I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

Copies of documents **FP7** and **NPL6** are submitted.

A concise explanation of the relevance of the non-English language document(s) appears below in accordance with 37 C.F.R. § 1.98(a)(3).

Document **FP7**, JP 09-172962 A, is in a foreign language. It is believed that **NPL6** is an English language Abstract and machine translation of document **FP7**.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bonnie W. Nannenga-Combs, Ph.D.
Attorney for Applicant
Registration No. 67,836

Date: March 12, 2012

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1483259_1.DOCX